Icon (NASDAQ:ICLR) Stock: Insider Ciaran Murray Sells 3,452 Shares

Icon Plc (NASDAQ:ICLR) Director Ciaran Murray sold 3,452 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $205.66, for a total transaction of $709,938.32. Following the completion of the transaction, the director directly owned 17,000 shares in the company, valued at approximately $3,496,220. This represents a 16.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Ciaran Murray also recently made the following trade(s):

• On Tuesday, August 11th, Ciaran Murray sold 2,677 shares of Icon stock. The shares were sold at an average price of $164.29, for a total value of $439,804.33.

Icon Price Performance

Shares of NASDAQ ICLR opened at $201.65 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.32 and a quick ratio of 1.32. Icon Plc has a 1-year low of $66.57 and a 1-year high of $219.04. The company has a market capitalization of $15.44 billion, a price-to-earnings ratio of 34.71, a PEG ratio of 11.25 and a beta of 1.19. The business has a 50-day moving average of $174.57 and a 200-day moving average of $146.92.

Icon (NASDAQ:ICLR) last released its quarterly earnings results on Tuesday, October 27th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.62 by $0.04. Icon had a return on equity of 7.73% and a net margin of 5.45%. The firm had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same period in the previous year, the company posted $3.31 EPS. Icon’s revenue for the quarter was down .9% on a year-over-year basis. On average, equities analysts anticipate that Icon Plc will post 9.71 EPS for the current fiscal year.

Institutional Trading of Icon

A number of institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC boosted its stake in Icon by 24.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 52,155 shares of the medical research company’s stock valued at $8,441,000 after purchasing an additional 10,389 shares during the period. Buckhead Capital Management LLC grew its position in Icon by 0.9% in the 3rd quarter. Buckhead Capital Management LLC now owns 25,591 shares of the medical research company’s stock worth $4,350,000 after purchasing an additional 218 shares during the last quarter. Commonwealth Equity Services LLC grew its position in Icon by 13.5% in the 3rd quarter. Commonwealth Equity Services LLC now owns 5,259 shares of the medical research company’s stock worth $894,000 after purchasing an additional 625 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its stake in shares of Icon by 0.4% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 20,762 shares of the medical research company’s stock valued at $3,529,000 after purchasing an additional 79 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Icon in the third quarter valued at approximately $38,000. 95.61% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. William Blair upgraded Icon to a “strong-buy” rating in a research note on Thursday, July 30th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $250.00 price target on shares of Icon in a research note on Thursday, October 29th. Evercore reaffirmed an “outperform” rating and issued a $240.00 price target on shares of Icon in a report on Wednesday, October 28th. TD Cowen increased their price objective on shares of Icon from $197.00 to $254.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Finally, Truist Financial raised their price objective on shares of Icon from $209.00 to $268.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $213.76.

About Icon

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.